Patents by Inventor Mark S. Segal

Mark S. Segal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and methods for modulating activity of bone marrow derived cells
    Patent number: 10493131
    Abstract: The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: December 3, 2019
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Kirk P. Conrad, Mark S. Segal
  • MATERIALS AND METHODS FOR MODULATING ACTIVITY OF BONE MARROW DERIVED CELLS
    Publication number: 20140242074
    Abstract: The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating 5 conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.
    Type: Application
    Filed: August 30, 2012
    Publication date: August 28, 2014
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Kirk P. Conrad, Mark S. Segal
  • Materials and methods for monitoring vascular endothelial function
    Publication number: 20040110241
    Abstract: The subject invention concerns a method of monitoring a patient's vascular endothelial function by obtaining a test blood specimen from the patient; measuring the amount of circulating endothelial cells (CECs), endothelial progenitor cells (EPCs), or both within the test blood specimen; and determining the state of activation of CECs and/or EPCs within the test blood specimen. The subject invention further pertains to methods of monitoring responsiveness to a vascular therapy, such as a statin-based therapy, using the quantity and surface phenotype of CECs and/or EPCs as diagnostic or prognostic indicators of vascular health, and particularly vascular endothelial health, before, during, or after the vascular therapy.
    Type: Application
    Filed: December 6, 2002
    Publication date: June 10, 2004
    Inventor: Mark S. Segal